TABLE 1.
Clinical characteristics of control, beryllium sensitisation (BeS) and chronic beryllium disease (CBD) subjects
| Controls
|
BeS | CBD | ||
|---|---|---|---|---|
| ND-Con | NE-Con | |||
| Subjects | 10 | 10 | 20 | 20 |
| Age years | 55.5 (50–62) | 62 (55–73) | 56 (39–68) | 62.5 (50–81) |
| Male/female | 8/2 | 8/2 | 17/3 | 16/4 |
| Race White/African-American/other | 9/0/1 | 10/0/0 | 19/0/1 | 19/0/1 |
| Duration since first exposure years | 27.8±14.6 | 24.7±7.8 | ||
| Smoking status current/ex/never | 0/1/9 | 0/0/10 | 0/3/17 | 0/5/15 |
| FEV1 L | 2.9±0.74 | 2.71±0.57 | ||
| FEV1 % pred | 83.47±16.63 | 84.80±17.46 | ||
| FVC L | 3.78±0.89 | 3.51±0.74 | ||
| FVC % pred | 83.11±12.58 | 82.85±16.67 | ||
| TLC L | 6.69±1.46 | 6.47±1.15 | ||
| TLC % pred | 105.42±14.42 | 106.30±17.78 | ||
| DLCO | 26.41±7.03 | 24.41±9.23 | ||
| DLCO % pred | 79.84±18.53 | 76.63±23.04 | ||
| Inhaled corticosteroids | 0 (0) | 6 (30)# | ||
| BAL cells | ||||
| WBC count ×106 | 36.9±22.1 | 43.1±28.4 | ||
| Lymphocytes % | 7.6±5.9 | 17.9±13.0# | ||
Data are presented as n, median (range), mean±SE or n (%). ND-Con: beryllium-exposed nondiseased control group; NE-Con: nonexposed nondiseased control group; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; TLC: total lung capacity; DLCO: diffusing capacity of the lung for carbon monoxide; BAL: bronchoalveolar lavage; WBC: white blood cell.
#
p<0.01.